These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 38707644)

  • 21. Mild cognitive impairment: an opportunity to identify patients at high risk for progression to Alzheimer's disease.
    Levey A; Lah J; Goldstein F; Steenland K; Bliwise D
    Clin Ther; 2006 Jul; 28(7):991-1001. PubMed ID: 16990077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Face-Name Associative Recognition Deficits in Subjective Cognitive Decline and Mild Cognitive Impairment.
    Polcher A; Frommann I; Koppara A; Wolfsgruber S; Jessen F; Wagner M
    J Alzheimers Dis; 2017; 56(3):1185-1196. PubMed ID: 28106560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estimating Alzheimer's Disease Progression Rates from Normal Cognition Through Mild Cognitive Impairment and Stages of Dementia.
    Davis M; O Connell T; Johnson S; Cline S; Merikle E; Martenyi F; Simpson K
    Curr Alzheimer Res; 2018; 15(8):777-788. PubMed ID: 29357799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Folic acid with or without vitamin B12 for cognition and dementia.
    Malouf M; Grimley EJ; Areosa SA
    Cochrane Database Syst Rev; 2003; (4):CD004514. PubMed ID: 14584018
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is Mild Cognitive Impairment a Precursor of Alzheimer's Disease? Short Review.
    Janoutová J; Šerý O; Hosák L; Janout V
    Cent Eur J Public Health; 2015 Dec; 23(4):365-7. PubMed ID: 26841152
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Neuropsychological impairment in the early Alzheimer's disease].
    Traykov L; Rigaud AS; Cesaro P; Boller F
    Encephale; 2007; 33(3 Pt 1):310-6. PubMed ID: 17675928
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development, Application, and Results from a Precision-medicine Platform that Personalizes Multi-modal Treatment Plans for Mild Alzheimer's Disease and At-risk Individuals.
    Keine D; Walker JQ; Kennedy BK; Sabbagh MN
    Curr Aging Sci; 2018; 11(3):173-181. PubMed ID: 30338750
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer's dementia in mild cognitive impairment patients.
    Pichet Binette A; Palmqvist S; Bali D; Farrar G; Buckley CJ; Wolk DA; Zetterberg H; Blennow K; Janelidze S; Hansson O
    Alzheimers Res Ther; 2022 Mar; 14(1):46. PubMed ID: 35351181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of mild behavioural impairment and its association with cognitive and functional impairment in normal cognition, mild cognitive impairment, and mild Alzheimer's dementia.
    Park JI;
    Psychogeriatrics; 2024 May; 24(3):555-564. PubMed ID: 38403289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vitamin E for Alzheimer's disease and mild cognitive impairment.
    Isaac MG; Quinn R; Tabet N
    Cochrane Database Syst Rev; 2008 Jul; (3):CD002854. PubMed ID: 18646084
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Superior Memory Reduces 8-year Risk of Mild Cognitive Impairment and Dementia But Not Amyloid β-Associated Cognitive Decline in Older Adults.
    Dang C; Harrington KD; Lim YY; Ames D; Hassenstab J; Laws SM; Yassi N; Hickey M; Rainey-Smith SR; Robertson J; Rowe CC; Sohrabi HR; Salvado O; Weinborn M; Villemagne VL; Masters CL; Maruff P;
    Arch Clin Neuropsychol; 2019 Jul; 34(5):585-598. PubMed ID: 30272115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alzheimer's disease risk factors as mediators of subjective memory impairment and objective memory decline: protocol for a construct-level replication analysis.
    Hill NL; Mogle J
    BMC Geriatr; 2018 Oct; 18(1):260. PubMed ID: 30373526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Martínez G; Vernooij RW; Fuentes Padilla P; Zamora J; Flicker L; Bonfill Cosp X
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012884. PubMed ID: 29164602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Understanding the role of psychiatrists in the diagnosis and management of mild cognitive impairment and mild Alzheimer's disease dementia: a cross-sectional survey.
    Gopalakrishna G; Brunton S; Pruzin J; Alford S; Hamersky C; Sabharwal A
    BMC Psychiatry; 2023 Oct; 23(1):716. PubMed ID: 37794326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment.
    Lombardi G; Crescioli G; Cavedo E; Lucenteforte E; Casazza G; Bellatorre AG; Lista C; Costantino G; Frisoni G; Virgili G; Filippini G
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD009628. PubMed ID: 32119112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Perspectives of patients, care partners, and primary care physicians on management of mild cognitive impairment and mild Alzheimer's disease dementia.
    Brunton S; Pruzin JJ; Alford S; Hamersky C; Sabharwal A; Gopalakrishna G
    Postgrad Med; 2023 Jun; 135(5):530-538. PubMed ID: 37219410
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cholinergic receptor binding in unimpaired older adults, mild cognitive impairment, and Alzheimer's disease dementia.
    Sultzer DL; Lim AC; Gordon HL; Yarns BC; Melrose RJ
    Alzheimers Res Ther; 2022 Feb; 14(1):25. PubMed ID: 35130968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia.
    Claxton A; Baker LD; Hanson A; Trittschuh EH; Cholerton B; Morgan A; Callaghan M; Arbuckle M; Behl C; Craft S
    J Alzheimers Dis; 2015; 44(3):897-906. PubMed ID: 25374101
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beta to theta power ratio in EEG periodic components as a potential biomarker in mild cognitive impairment and Alzheimer's dementia.
    Azami H; Zrenner C; Brooks H; Zomorrodi R; Blumberger DM; Fischer CE; Flint A; Herrmann N; Kumar S; Lanctôt K; Mah L; Mulsant BH; Pollock BG; Rajji TK;
    Alzheimers Res Ther; 2023 Aug; 15(1):133. PubMed ID: 37550778
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Independent effects of white matter hyperintensities on cognitive, neuropsychiatric, and functional decline: a longitudinal investigation using the National Alzheimer's Coordinating Center Uniform Data Set.
    Puzo C; Labriola C; Sugarman MA; Tripodis Y; Martin B; Palmisano JN; Steinberg EG; Stein TD; Kowall NW; McKee AC; Mez J; Killiany RJ; Stern RA; Alosco ML
    Alzheimers Res Ther; 2019 Jul; 11(1):64. PubMed ID: 31351489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.